EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert A Huddart, Earle F Burgess, Nadine Houede, Severine Banek, Valentina Guadalupi, Ja Hyeon Ku, Begoña P Valderrama, Ben Tran, Spyros Triantos und 7 weitere

New England Journal of Medicine · 23.11.2023 · 389 (21) · 1961-1971

DOI: 10.1056/nejmoa2308849 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.11.2023. Verfasst von Yohann Loriot und 18 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncolo…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor. Die Arbeit wurde bisher 363-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Transitional CellUrinary Bladder NeoplasmsReceptors, Fibroblast Growth FactorAntineoplastic AgentsAdultHumansAntineoplastic Combined Chemotherapy ProtocolsDocetaxelImmune Checkpoint InhibitorsPyrazolesQuinoxalinesVinblastine

Substanzen

Antibodies, Monoclonal, HumanizedDocetaxelImmune Checkpoint InhibitorsReceptors, Fibroblast Growth FactorAntineoplastic AgentserdafitinibPyrazolesQuinoxalinesvinflunineVinblastine

Autor:innen und Institutionen

  • From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire…

Förderung

  • Janssen Research and Development

Zitieren

APA

Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., Ku, J. H., Valderrama, B. P., Tran, B., Triantos, S., Kean, Y., Akapame, S., Deprince, K., Mukhopadhyay, S., Stone, N. L., Siefker-Radtke, A. O., & THOR Cohort 1 Investigators (2023). Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 389(21), 1961-1971. https://doi.org/10.1056/nejmoa2308849

Vancouver

Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine. 2023;389(21):1961-1971. doi:10.1056/nejmoa2308849

BibTeX
@article{Loriot2023,
  author = {Loriot, Yohann and Matsubara, Nobuaki and Park, Se Hoon and Huddart, Robert A and Burgess, Earle F and Houede, Nadine and Banek, Severine and Guadalupi, Valentina and Ku, Ja Hyeon and Valderrama, Begoña P and Tran, Ben and Triantos, Spyros and Kean, Yin and Akapame, Sydney and Deprince, Kris and Mukhopadhyay, Sutapa and Stone, Nicole L and Siefker-Radtke, Arlene O and THOR Cohort 1 Investigators, THOR Cohort 1 Investigators},
  title = {Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {21},
  pages = {1961--1971},
  doi = {10.1056/nejmoa2308849}
}
Kostenlos starten →